pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2015-25-3-368-372pulmo-588Research ArticleОБЗОРЫREVIEWОт качественной спирометрии к оптимальной бронхолитической терапии (аналитический обзор)From high-quality spirometry to optimal bronchodilator therapy (analytical review)ВизельА. А.Vizel'A. A.

д. м. н., профессор, зав. кафедрой фтизиопульмонологии ГБОУ ВПО «Казанский государственный медицинский университет» Минздрава России; тел.: (987) 296-25-99

MD, Professor, Head of Department of Phthisiology and Pulmonology, State Institution  Kazan State Medical University, Healthcare Ministry of Russia; tel.: (987) 296-25-99;

lordara@inbox.ruВизельИ. Ю.Vizel'I. Yu.

к. м. н., ассистент кафедры фтизиопульмонологии ГБОУ ВПО «Казанский государственный медицинский университет» Минздрава России; тел.: (843) 279-80-03

PhD, Assistant Lecturer at the Department of Phthisiology and Pulmonology, State Institution  Kazan State Medical University, Healthcare Ministry of Russia; tel.: (843) 279-80-03;

tatpulmo@mail.ruГБОУ ВПО «Казанский государственный медицинский университет» Минздрава России: 420012, Республика Татарстан, Казань, ул. Бутлерова, 49РоссияState Institution Kazan State Medical University, Healthcare Ministry of Russia: 49, Butlerova str., Kazan', 420012, Tatarstan RepublikRussian Federation201531072015253368372Copyright © Визель А.А., Визель И.Ю., 20152015Визель А.А., Визель И.Ю.Vizel' A.A., Vizel' I.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/588

Представлен аналитический обзор, современных методов доставки ингаляционных средств в дыхательные пути. Обоснована значимость проведения спирометрии и использования результатов исследования функции внешнего дыхания для выбора ингалятора. Отмечены преимущества и недостатки различных устройств. Приведены данные о применении новых комбинированных препаратов – адреномиметических и холиноблокирующих бронхолитиков длительного действия.

Modern methods of inhaled drug delivery to the respiratory tract were discussed in this analytical review. Significance of spirometry and the importance of spirometric results for the inhaler choice were substantiated. Advantages and disadvantages of different inhalation devices were described. Efficacy of inhalational combination of long-acting anticholinergics and beta-agonists was also reviewed.

ингаляторспирометриябронхолитический препаратinhalerspirometrybronchodilatorReferencesMiller M.R., Hankinson J., Brusasco V. et al. ATS / ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26 (2): 319–338.Miller M.R., Hankinson J., Brusasco V. et al. ATS / ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26 (2): 319–338.Müller-Brandes C., Krämer U., Gappa M. et al. LUNOKID: can numerical American Thoracic Society / European Respiratory Society quality criteria replace visual inspection of spirometry? Eur. Respir J. 2014; 43 (5): 1347–1356.Müller-Brandes C., Krämer U., Gappa M. et al. LUNOKID: can numerical American Thoracic Society / European Respiratory Society quality criteria replace visual inspection of spirometry? Eur. Respir J. 2014; 43 (5): 1347–1356.Satake M., Shioya T., Uemura S. et al. Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 153–158.Satake M., Shioya T., Uemura S. et al. Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 153–158.Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies: ERS / ISAM Task force report. Eur. Respir. J. 2011; 37 (6): 1308–1331.Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies: ERS / ISAM Task force report. Eur. Respir. J. 2011; 37 (6): 1308–1331.Sheth P., Stein S.W., Myrdal P.B. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers. AAPS PharmSciTech. 2015; 16 (1): 192–201.Sheth P., Stein S.W., Myrdal P.B. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers. AAPS PharmSciTech. 2015; 16 (1): 192–201.de Oliveira P.D., Menezes A.M., Bertoldi A.D. et al. Assessment of inhaler techniques employed by patients with respiratory diseases in southern Brazil: a population-based study. J. Bras. Pneumol. 2014; 40 (5): 513–520.de Oliveira P.D., Menezes A.M., Bertoldi A.D. et al. Assessment of inhaler techniques employed by patients with respiratory diseases in southern Brazil: a population-based study. J. Bras. Pneumol. 2014; 40 (5): 513–520.Ganguly A., Das A.K., Roy A. et al. Study of proper use of inhalational devices by bronchial asthma or COPD patients attending a tertiary care hospital. J. Clin. Diagn. Res. 2014; 8 (10): HC04–07.Ganguly A., Das A.K., Roy A. et al. Study of proper use of inhalational devices by bronchial asthma or COPD patients attending a tertiary care hospital. J. Clin. Diagn. Res. 2014; 8 (10): HC04–07.Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug. Deliv. Rev. 2014; 75: 18–31.Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug. Deliv. Rev. 2014; 75: 18–31.Sliwiński P., Chazan R., Dąbrowiecki P. et al. Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD. Pneumonol. Alergol. Pol. 2014; 8 2(3): 300–310.Sliwiński P., Chazan R., Dąbrowiecki P. et al. Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD. Pneumonol. Alergol. Pol. 2014; 8 2(3): 300–310.Du P., Du J., Smyth H.D. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. AAPS PharmSciTech. 2014; 15 (6): 1417–1428.Du P., Du J., Smyth H.D. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. AAPS PharmSciTech. 2014; 15 (6): 1417–1428.Mehta R., Daley-Yates P.T., Jenkins K. et al. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler. Pulm. Pharmacol. Ther. 2014; 29 (1): 66–73.Mehta R., Daley-Yates P.T., Jenkins K. et al. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler. Pulm. Pharmacol. Ther. 2014; 29 (1): 66–73.Azouz W., Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim. Care Respir. J. 2012; 21 (2): 208–213.Azouz W., Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim. Care Respir. J. 2012; 21 (2): 208–213.Kanabuchi K., Kondo T., Tanigaki T. et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J. Exp. Clin. Med. 2011; 36 (1): 1–4.Kanabuchi K., Kondo T., Tanigaki T. et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J. Exp. Clin. Med. 2011; 36 (1): 1–4.Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry powder inhalers. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (1): 35–42.Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 353–363.Kondo T., Tanigaki T., Hibino M. et al. Resistances of dry powder inhalers and training whistles and their clinical significance. Arerugi. 2014; 63 (10): 1325–1329.Kondo T., Tanigaki T., Hibino M. et al. Resistances of dry powder inhalers and training whistles and their clinical significance. Arerugi. 2014; 63 (10): 1325–1329.Weers J.G., Clark A.R., Rao N. et al. In vitro-in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler#R. Aerosol. Med. Pulm. Drug Deliv. 2014, Dec. 17 [Epub ahead of print].Weers J.G., Clark A.R., Rao N. et al. In vitro-in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler#R. Aerosol. Med. Pulm. Drug Deliv. 2014, Dec. 17 [Epub ahead of print].Molimard M., Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (3): 219–228.Molimard M., Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (3): 219–228.Frampton J.E. QVA149 (indacaterol / glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.Frampton J.E. QVA149 (indacaterol / glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488.Prakash A., Babu K.S., Morjaria J.B. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 111–123.Prakash A., Babu K.S., Morjaria J.B. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 111–123.

The authors declare that there are no conflicts of interest present.